(Q43958437)

English

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment (English)

1 reference

Europe PubMed Central

28 November 2017

mild cognitive impairment

1 reference

based on heuristic

inferred from title

author name string

Bruce H Morimoto

1

1 reference

Europe PubMed Central

28 November 2017

Don Schmechel

2

1 reference

Europe PubMed Central

28 November 2017

Joe Hirman

3

1 reference

Europe PubMed Central

28 November 2017

Andrew Blackwell

4

1 reference

Europe PubMed Central

28 November 2017

Julian Keith

5

1 reference

Europe PubMed Central

28 November 2017

Michael Gold

6

1 reference

Europe PubMed Central

28 November 2017

AL-108-211 Study

7

1 reference

Europe PubMed Central

28 November 2017

publication date

13 April 2013

1 reference

Europe PubMed Central

28 November 2017

Dementia and Geriatric Cognitive Disorders

1 reference

Europe PubMed Central

28 November 2017

35

1 reference

Europe PubMed Central

28 November 2017

5-6

1 reference

Europe PubMed Central

28 November 2017

325-336

1 reference

Europe PubMed Central

28 November 2017

Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

'Prodromal Alzheimer's disease': a more useful concept than mild cognitive impairment?

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Current concepts in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Subtype of mild cognitive impairment and progression to dementia and death

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Neuropathologic features of amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Ginkgo biloba for prevention of dementia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks.

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Episodic and semantic memory in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1159%2F000348347

21 January 2018

Identifiers

10.1159/000348347

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43958437&oldid=2104799495"